Stock GME GERATHERM MEDICAL AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Geratherm Medical AG

Equities

GME

DE0005495626

Market Closed - Xetra
Other stock markets
 11:36:04 2024-07-01 EDT 		5-day change 1st Jan Change
4.02 EUR -0.99% Intraday chart for Geratherm Medical AG -3.83% -25.56%
06-20 Geratherm Medical AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Geratherm Medical AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company sustains low margins.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
GERATHERM MEDICAL AG Stock Geratherm Medical AG
-25.56% 23.39M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.24% 181B
C+
MEDTRONIC PLC Stock Medtronic plc
-6.39% 101B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.97% 67.54B
A
DEXCOM, INC. Stock DexCom, Inc.
-9.61% 45.09B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.84% 44.37B
B-
HOYA CORPORATION Stock Hoya Corporation
+5.36% 40.7B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+12.69% 29.85B
B
TERUMO CORPORATION Stock Terumo Corporation
+10.26% 24.49B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-7.83% 23.99B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. GME Stock
  4. Ratings Geratherm Medical AG